SIGN IN
Email Address
Password

Evolving Long-Term Goals in IBD: Effective Strategies for Maintaining Response and Remission



This CME Activity has expired and is no longer available for credit. Your test score will not be saved.
To start this activity, click "Begin" at the bottom of this page.

Evolving Long-Term Goals in IBD: Effective Strategies for Maintaining Response and Remission

Release Date:

May 04, 2012

Expiration Date:

May 04, 2013

Topics:

Gastrointestinal Disorders
Genitourinary Medicine
Pediatrics

Specialty:

Adolescent Medicine
Gastroenterology / Proctology
Pediatrics

Profession:

Other Healthcare Professional
Physician

Format:

Interactive Monograph

Credits:

1.00 / AMA PRA Category 1 Credit(s)TM


Program Description:

Maintaining symptom control and disease remission is essential to minimizing short- and long-term complications and improving outcomes and quality of life for patients with inflammatory bowel disease (IBD). Although the treatment of active IBD has improved considerably, a high rate of relapse is still associated with the disease and maintenance of remission remains an unmet medical need. This program provides practical strategies for optimizing treatment and adherence for adult and pediatric patients with IBD. Drawing on current research and their own clinical experience, the faculty members explore issues of high relevance to clinicians who provide care to patients with IBD.

INTENDED AUDIENCE:

This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with IBD.

Activity Objectives:

After taking part in this educational activity, participants should be better able to:

  • Apply evidence-based treatment guidelines to maintain response and remission in adult patients with IBD

  • Design effective monitoring and maintenance strategies for pediatric patients with IBD

  • Educate patients with IBD about the importance of adhering to maintenance therapy


Credits Type Accreditation Statement Designation Statement
1.00 AMA PRA Category 1 Credit(s)TM The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty:

Stephen B. Hanauer, MD—Program Chair
Professor of Medicine and Clinical Pharmacology
Chief, Section of Gastroenterology, Hepatology, and Nutrition
The University of Chicago Pritzker School of Medicine
Chicago, Illinois

Asher A. Kornbluth, MD
Clinical Professor of Medicine
The Inflammatory Bowel Disease Center
The Henry D. Janowitz Division of Gastroenterology
Mount Sinai School of Medicine
New York, New York

Joel R. Rosh, MD
Associate Professor of Pediatrics
University of Medicine and Dentistry of New Jersey
Director, Pediatric Gastroenterology
Goryeb Children’s Hospital/Atlantic Health
Morristown, New Jersey

William J. Sandborn, MD
Clinical Professor of Medicine
Chief, Division of Gastroenterology
Director, Inflammatory Bowel Disease Center
University of California San Diego
La Jolla, California

Click to Expand/Collapse Disclosures:

The University of Chicago and Curatio CME Institute adhere to the Accreditation Council for Continuing Medical Education Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Faculty
Stephen B. Hanauer, MD,
has disclosed the following relevant financial relationships:
Consultant: Abbott Laboratories, Elan Pharmaceuticals, Janssen, Meda Pharmaceuticals, Millennium, Prometheus, Salix Pharmaceuticals, Shire Pharmaceuticals, UCB Pharma, Warner Chilcott
Clinical Research: Abbott Laboratories, Elan Pharmaceuticals, Janssen, Millennium, Prometheus Laboratories, Salix Pharmaceuticals, Shire Pharmaceuticals, UCB Pharma, Warner Chilcott

Asher A. Kornbluth, MD, has disclosed the following relevant financial relationships:
Grant/Research Support: Abbott Laboratories, Centocor, Millennium, Osiris
Consultant/Advisory Board: Abbott Laboratories, Alaven, Axcan, Biogen, Centocor, Prometheus, Takeda, Warner Chilcott
Speakers Bureau/Honoraria: Abbott Laboratories, Axcan, Centocor, Prometheus, Warner Chilcott

Joel R. Rosh, MD, has disclosed the following relevant financial relationships:
Grant/Research Support: Abbott Laboratories, Centocor, UCB Pharma
Consultant/Advisory Board: Abbott Laboratories, Centocor
Speakers Bureau/Honoraria: Abbott Nutrition

William J. Sandborn, MD, has disclosed the following relevant financial relationships:
Consultant/Honorarium: Abbott Laboratories, Alfa Wasserman, Amgen, Astellas Pharma, Athersys, Axcan Pharma (now Aptalis), Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Cosmo Technologies, Coronado Biosciences, Eli Lilly, Elan Pharmaceuticals, Enteromedics, EnGene, Exagen Diagnostics, Ferring Pharmaceuticals, Funxional Therapeutics Limited, Genentech (now Roche), Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals (previously Microbia), Janssen (previously Centocor), Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lycera Corporation, Meda Pharmaceuticals (previously Alaven Pharmaceuticals), Merck Research Laboratories, Millennium Pharmaceuticals (subsequently merged with Takeda), NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Limited, Receptos, Relypsa, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Schering Plough Corporation (acquired by Merck), Shire Pharmaceuticals, Sigmoid Pharma Limited, Targacept, Teva Pharmaceuticals, Therakos, Tillotts Pharma AG (acquired by Zeria Pharmaceutical Co), TxCell SA, UCB Pharma, Vascular Biogenics Limited (VBL), Warner Chilcott UK Limited, Wyeth (now Pfizer)
Lecturer: Abbott Laboratories, Bristol-Myers Squibb, Janssen (previously Centocor)
Research Support: Abbott Laboratories, Bristol-Myers Squibb, Centocor (now Janssen), Genentech, GlaxoSmithKline, Millennium Pharmaceuticals (now Takeda), Pfizer, Procter and Gamble, Shire Pharmaceuticals, UCB Pharma
Research Grant: Abbott Laboratories, Bristol-Myers Squibb, Centocor (now Janssen), Genentech, GlaxoSmithKline, Millennium Pharmaceuticals (now Takeda), Pfizer, Procter and Gamble, Shire Pharmaceuticals, UCB Pharma

Dr. Sandborn discusses the unlabeled or investigational use of a commercial product.

Curatio CME Institute
The employees of Curatio CME Institute have disclosed no relevant financial relationships.

The University of Chicago
The employees of the Center for Continuing Medical Education have disclosed no relevant financial relationships.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the University of Chicago, Abbott, Aptalis, Shire, UCB, and Warner Chilcott do not recommend the use of any agent outside the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, the University of Chicago, Abbott, Aptalis, Shire, UCB, or Warner Chilcott. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

To view the unapproved product use table, please click here.

Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

Commercial Supporter
Support for this activity has been provided by educational grants from Abbott, Aptalis, Shire, UCB, and Warner Chilcott.

Accredited Provider
Co-sponsored by

          

If you have any questions relating to the accreditation of this activity, please contact The University of Chicago Center for Continuing Medical Education by email at cme@bsd.uchicago.edu or by phone at 773-702-1056.

Privacy Policy
To view the myCME privacy policy, please click here.

To view the University of Chicago Center for Continuing Medical Education privacy policy, please click here.

Instructions:

To obtain credit, a score of 70% or better is required. This CME activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all pre-survey questions, post-test questions, completed the evaluation survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

Click to Expand/Collapse SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.



Home | Browse By Disease | Browse By Specialty | Browse By Profession | About HME | Contact Us | Web Support

© 2013 Haymarket Media, Inc.

Your use of this website constitutes acceptance of Haymarket Medical Education's Privacy Policy and Terms & Conditions

Haymarket Medical Education